Clincosm LogoSign in Get a demo

A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease

Sponsor
Lancaster University (Other)
Overall Status
Completed
CT.gov ID
NCT02464293
Collaborator
Manchester University NHS Foundation Trust (Other)
16
Enrollment
1
Location
1
Arm
32
Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a pilot study to see whether mindfulness-based cognitive therapy, which is a type of psychological therapy, is able to improve the psychological wellbeing of people who have the gene for Huntington's disease.

Condition or Disease Intervention/Treatment Phase
  • Other: Mindfulness-based cognitive therapy
 N/A

Detailed Description

Huntingdon's disease (HD) is a genetic neurodegenerative condition which causes problems with movement, coordination and cognitive functioning, and emotional difficulties are also commonly experienced. It is believed to affect around five to ten in 100,000 people of European descent, with recent UK estimates as high as 11.2-13.5. Each child of an affected person has a 50% chance of inheriting the condition. As age of diagnosis is typically around 35-55, with time from diagnosis to death around 20 years, those who are diagnosed have often seen their parents affected by the condition.

Many people at various stages of HD (including those who carry the gene but are pre-symptomatic) experience low mood, anxiety and other psychological difficulties. Indeed, alongside functional capacity, mood may be one of the main factors which contributes to health related quality of life, more so than discrete motor problems, or cognitive impairment. In addition, reports from patients suggest emotional and social concerns are important for individuals with the condition at the pre-symptomatic stage, and these concerns remain throughout the disease course. Medication may be effective to alleviate psychological difficulties for some people, but its efficacy has not been conclusively proven and it is not suitable for all. Psychological interventions may provide an alternative or additional way of alleviating distress.

Although it is commonly presumed that biological factors are the main determinants of psychological distress in people with HD, several studies have indicated that, while these may indeed be important, psychological factors are also significant. For example beliefs about the disease and coping mechanisms are associated with poorer mental health and higher levels of depression. Such psychological beliefs and coping patterns can be adaptively changed using psychological interventions, for example cognitive-based psychological therapies.

Little progress has been reported on the development of psychological interventions in HD despite the fact that people with HD have expressed an interest in psychological approaches and these are currently being successfully developed for people with other neurological conditions (e.g., in people with Parkinson's disease). It is therefore proposed to pilot mindfulness-based cognitive therapy (MBCT) which, although originally developed to help people with remitted depression from relapse, has been increasingly used to help people with current difficulties. It has also been piloted with people with Parkinson's disease who found it an acceptable intervention and reported improvements in self-management and psychological wellbeing. In general, MBCT has also recorded other gains including improved sleep quality and social functioning. It has also received sufficient evidence for it to be a recommended approach in the UK NICE guidelines for people with a history of depression. MBCT can also reduce anxiety and provides group support. There are also indications that mindfulness training can improve neurocognitive functioning, even in people with neurodegenerative disease. Finally, a psychological therapy subgroup within the European Huntington's Disease Network has recently been formed, thus indicating the rise of interest in psychological approaches and the timely nature of this work.

Hence this study will provide the first indication of whether MBCT, a therapeutic approach with an established evidence base, would be acceptable and useful for people with HD. In order to meet this aim, MBCT will be delivered to two groups, one to individuals who carry the gene but are pre-symptomatic and one to individuals who have begun to experience symptoms but are at an early stage of the disease course.

Approaches to outcome evaluation should be incremental, with lower cost studies, e.g., qualitative investigations and case studies, being conducted before investment in randomised controlled trials is considered. Thus this study will follow this guidance by collecting both qualitative and quantitative data. The qualitative data will be analysed using interpretative phenomenological analysis, a methodology previously used in other qualitative studies on MBCT. Semi-structured interviews will provide data on the acceptability of the intervention and detailed accounts of participants' experience after the intervention has been provided. This will inform whether the MBCT intervention needs to be changed or adapted in further trials. The quantitative data will be used to provide basic pre and post intervention comparisons on a number of outcome variables relevant to MBCT, with the hypothesis that performance on these measures will improve post training. These data will also be used to estimate effect sizes for further trials so that these are suitably powered.

Given the considerable physical, cognitive and emotional consequences of the disease, HD not only affects the person with HD, but also those with whom they live, even in the pre-clinical phase. Family members often become caregivers and can have a reduced quality of life as a result, including experiencing low mood themselves. In fact, caregiver burden and caregiver depression is associated with depression of the person with HD and, alongside motor disturbances, depression of the person with HD is one of the main predictors of caregiver burden. Partners of people with HD can also experience reduced satisfaction with their relationship, sometimes more so than the person with HD themselves.

Thus this study will also investigate the views of a family member (e.g. partner, parent, child) of the person participating in the intervention. As the intervention is aimed at alleviating psychological distress in the person with HD, it is hypothesised that this in turn will also have an effect on the family member's wellbeing. Also, higher levels of mindfulness are associated with higher levels of satisfaction in partner relationships, perhaps due to more adaptive conflict resolution and better emotional recognition and management. Participants in MBCT have reported increased empathy and perspective taking, being more able to respond mindfully in relationships. Thus increased mindfulness of the person with HD may benefit family and social relationships.

In addition, caregivers' views about the symptoms or quality of life of the person with HD may not always match the person with HD themselves. Furthermore, certain symptom changes which are beneficial to the person with HD may not be so to the caregiver, and thus the caregiver can offer an alternative perspective of the wellbeing (including behavioural and psychological changes) of the person with HD.

Both qualitative and quantitative data will be collected from a family member or close friend of the person with HD, where such a person is available and willing to take part. Semi-structured interviews with the family member will explore their perceptions on the acceptability of the intervention and experiences of the person with HD, as well as the impact on the family member personally and the wider family system. Data collected pre and post the intervention will assess any changes in their psychological wellbeing, caregiver burden and family relationships, with the hypothesis that wellbeing and relationships will improve post training and caregiver burden will decrease.

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease
Study Start Date :
Jun 1, 2015
Actual Primary Completion Date :
Jan 31, 2018
Actual Study Completion Date :
Jan 31, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: mindfulness-based cognitive therapy

Other: Mindfulness-based cognitive therapy
An 8 week course of mindfulness-based cognitive therapy

Outcome Measures

Primary Outcome Measures

  1. depression post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in Hospital Anxiety and Depression Scale (HADS) depression score pre to post intervention (People with HD only)

  2. depression at 3 months [3 months post-intervention]

    Change in HADS depression score pre to 3 months post intervention

  3. depression at 1 year [1 year post-intervention]

    Change in HADS depression score pre to 1 year post intervention

Secondary Outcome Measures

  1. depression mid-course [4 weeks after start of intervention]

    Change in HADS depression score pre to mid-course (4 weeks after start) (people with HD only)

  2. anxiety mid-course [4 weeks after start of intervention]

    Change in HADS anxiety score pre to mid-course (4 weeks after start) (people with HD only)

  3. anxiety post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in HADS anxiety score pre to post-intervention (people with HD only)

  4. anxiety at 3 months [3 months post-intervention]

    Change in HADS anxiety score pre to 3 months post intervention

  5. anxiety at 1 year [1 year post-intervention]

    Change in HADS anxiety score pre to 1 year post intervention

  6. stress mid course [4 weeks after start of intervention]

    Change in Depression Anxiety and Stress Scale (DASS) stress score pre to mid-course (4 weeks after start) (people with HD only)

  7. stress post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in DASS stress score pre to post course (people with HD only)

  8. stress at 3 months [3 months post-intervention]

    Change in DASS stress score pre to 3 months post intervention

  9. stress at 1 year [1 year post-intervention]

    Change in DASS stress score pre to 1 year post intervention

  10. mindfulness mid-course [4 weeks after start of intervention]

    Change in Five Factor Mindfulness Questionnaire (FFMQ) score pre to mid-course (4 weeks after start) (people with HD only)

  11. mindfulness post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in FFMQ score pre to post course (people with HD only)

  12. mindfulness at 3 months [3 months post-intervention]

    Change in FFMQ score pre to 3 months post intervention

  13. mindfulness at 1 year [1 year post-intervention]

    Change in FFMQ score pre to 1 year post intervention

  14. sleep post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in Pittsburgh Sleep Quality Index (PSQI) score pre to post course (people with HD only)

  15. sleep at 3 months [3 months post-intervention]

    Change in PSQI score pre to 3 months post intervention (people with HD only)

  16. sleep at 1 year [1 year post-intervention]

    Change in PSQI score pre to 1 year post intervention (people with HD only)

  17. quality of life post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in World Health Organisation Quality of Life BREF) score (WHOQOL) pre to post course (people with HD only)

  18. quality of life at 3 months [3 months post-intervention]

    Change in WHOQOL score pre to 3 months post intervention

  19. quality of life at 1 year [1 year post-intervention]

    Change in WHOQOL score pre to 1 year post intervention

  20. positive affect post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in Positive And Negative Affect Scale (PANAS) positive items score pre to post course (people with HD only)

  21. positive affect at 3 months [3 months post-intervention]

    Change in PANAS positive items score pre to 3 months post intervention

  22. positive affect at 1 year [1 year post-intervention]

    Change in PANAS positive items score pre to 1 year post intervention

  23. coping post intervention [immediately post-intervention (up to two weeks afterwards)]

    Change in brief COPE score pre to post course (people with HD only)

  24. coping at 3 months [3 months post-intervention]

    Change in brief COPE score pre to 3 months post intervention

  25. coping at 1 year [1 year post-intervention]

    Change in brief COPE score pre to 1 year post intervention

  26. relationship satisfaction at 3 months [3 months post-intervention]

    Change in Relationship Assessment Scale (RAS) score pre to 3 months post intervention (relatives/friends only)

  27. relationship satisfaction at 1 year [1 year post-intervention]

    Change in RAS score pre to 1 year post intervention (relatives/friends only)

  28. carer burden at 3 months [3 months post-intervention]

    Change in carer burden inventory score pre to 3 months post intervention (relatives/friends only)

  29. carer burden at 1 year [1 year post-intervention]

    Change in carer burden inventory score pre to 1 year post intervention (relatives/friends only)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
For those with HD:

Patient at Manchester Centre for Genomic Medicine (UK)

  • All participants will have had genetic testing and shown to have the requisite CAG expansion on the huntingtin gene.

  • Participants must be pre-symptomatic or at stage 1 (still able to function at home and at work and handle financial affairs)

  • Clinical sign of depression (score on HADS of 7 or above)

  • No significant medication changes in 6 weeks prior to starting the course

For those who are relatives or friends of those with HD:
  • Must be a relative or friend of someone participating in the MBCT course
Exclusion Criteria:
  • Active suicidal intent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Central Manchester University Hospitals NHS Foundation Trust Manchester United Kingdom

Sponsors and Collaborators

  • Lancaster University
  • Manchester University NHS Foundation Trust

Investigators

  • Principal Investigator: Jane Simpson, PhD, Lancaster University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dr Jane Simpson, Research Director, Doctorate in Clinical Psychology, Lancaster University
ClinicalTrials.gov Identifier:
NCT02464293
Other Study ID Numbers:
  • EHDN Seed Fund Project 561
  • 15/NW/0238
First Posted:
Jun 8, 2015
Last Update Posted:
Jan 7, 2020
Last Verified:
Jan 1, 2020
Keywords provided by Dr Jane Simpson, Research Director, Doctorate in Clinical Psychology, Lancaster University
depression
anxiety
stress
Additional relevant MeSH terms:
Huntington Disease

Study Results

No Results Posted as of Jan 7, 2020